What Biohaven’s Avilar trade secret verdict means for the MoDE protein degradation platform
Biohaven and Yale won a $4 million MODA trade secret verdict, strengthening the platform narrative as BHV-1300 enters Phase 3.
Pharma & Biotech
Pharma & Biotech
Could deupirfenidone beat an approved IPF drug? Celea starts the Phase 3 test that will decide
Celea Therapeutics has begun an unusually ambitious Phase 3 program designed to prove that deupirfenidone is superior, rather than merely comparable, to the established antifibrotic pirfenidone. The approximately 1,100-patient trial could support a United States registration application if successful, but its 2029 readout leaves the company facing a long development period and an increasingly competitive
Pharma & Biotech
Memento Medicines launches with $93m, but can MMT-205 challenge retinal drug leaders?
Discover how Memento Medicines plans to challenge retinal drug leaders with $93 million, MMT-205 and a direct Tie2 activation strategy.